Labor Department to Require PBM Pricing Transparency
New federal regulations will mandate that pharmacy benefit managers disclose revenue and pricing data to employers.
Updated on Oct. 28, 2026 in Healthcare
Live Poll
Should the government mandate that pharmacy benefit managers disclose their drug pricing and revenue data?
Starting in July 2027, the U.S. Labor Department will require pharmacy benefit managers (PBMs) to disclose their revenue and pricing structures to employer clients. This initiative aims to increase transparency around rebates and payments from drug manufacturers and pharmacies.
Why it matters
The regulation intends to curb rising health care costs by forcing PBMs to disclose their compensation and spread pricing practices. Greater visibility into these financial arrangements is expected to help self-insured employers better manage their prescription drug spending.
Pharmacy benefit managers will be required to report their actual earnings every six months to their employer clients. This disclosure mandate specifically targets rebates and payments collected through affiliated group purchasing organizations.
The players
U.S. Labor Department
This federal agency is responsible for occupational safety, wage and hour standards, and the administration of various employee benefit regulations.
U.S. Congress
The bicameral legislative branch of the federal government holds the power to pass laws that regulate national healthcare policies and industry transparency.
The details
The new rule grants self-insured employers the authority to audit PBM operations to verify payment data and pricing. PBMs must provide this information upfront, ensuring that compensation from drugmakers and pharmacies is fully visible to the plan sponsors.
Timeline
February 2026: Congress passed a separate law regarding prescription drug transparency.
July 2027: The Labor Department regulation takes effect.
2028: Most provisions of the congressional transparency law take effect.
Market Landscape
This regulation follows the pattern set by federal efforts to increase oversight of pharmaceutical spending and supply chain finance. It mirrors a broader trend of shifting market dynamics as lawmakers move to limit the opaque profit models used by industry intermediaries.
Employers who self-insure their health plans will gain new tools to audit their drug spending and demand clearer pricing from their benefit managers. These changes are designed to help control health care costs, potentially impacting long-term premiums for those covered by employer plans.
The takeaway
Increased financial transparency in the PBM industry may shift how prescription drug benefits are negotiated between companies and pharmacy managers. Employers should prepare to utilize new audit rights to assess whether their current benefit structures align with market standards.
What happens next
The mandatory reporting regulation is scheduled to take effect on July 1, 2027. Additionally, in 2028, most provisions from the broader congressional transparency law passed in 2026 will go into effect.
Further reading
Learn more about federal oversight of medical costs in the United States Healthcare section.
Live Poll
Should the government mandate that pharmacy benefit managers disclose their drug pricing and revenue data?
